Vernalis PLC Director/PDMR Shareholding (3997L)
September 30 2016 - 10:55AM
UK Regulatory
TIDMVER
RNS Number : 3997L
Vernalis PLC
30 September 2016
30 September 2016
LSE: VER
Vernalis plc
Director/PDMR Dealing
Vernalis plc (LSE: VER) today announces that Carol Ferguson,
Non-Executive Director of the Company today transferred 28,000
ordinary shares of 1 pence each ("Ordinary Shares") to her SIPP.
This was effected as set out in the notification below.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1. Details of PDMR / person closely associated with
them ("PCA")
--- ---------------------------------------------------------------------------
a) Name Carol Ferguson
--- ------------------------------ -------------------------------------------
2. Reason for the notification
--- ---------------------------------------------------------------------------
a) Position / status Non-Executive Director
--- ------------------------------ -------------------------------------------
b) Initial notification Initial notification
/ amendment
--- ------------------------------ -------------------------------------------
3. Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
--- ---------------------------------------------------------------------------
a) Name Vernalis plc
--- ------------------------------ -------------------------------------------
b) Legal Entity n/a
Identifier
--- ------------------------------ -------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--- ---------------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each ("Ordinary
the financial Shares")
instrument GB00B3Y5L754
--- ------------------------------ -------------------------------------------
b) Nature of the Sale of Ordinary Shares
transaction
--- ------------------------------ -------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) -------------- -----------------------
40.9106 pence 28,000 Ordinary Shares
-------------- -----------------------
--- ------------------------------ -------------------------------------------
d) Aggregated information
* Aggregated volume N/A - single transaction
* Aggregated price
* Aggregated total
--- ------------------------------ -------------------------------------------
e) Date of the transaction 30 September 2016 (UK)
--- ------------------------------ -------------------------------------------
f) Place of the London Stock Exchange, AIM
transaction
--- ------------------------------ -------------------------------------------
5. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--- ---------------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each ("Ordinary
the financial Shares")
instrument GB00B3Y5L754
Identification
code
--- ------------------------------ -------------------------------------------
b) Nature of the Purchase of Ordinary Shares by SIPP
transaction
--- ------------------------------ -------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ----------- -----------------------
41.5 pence 28,000 Ordinary Shares
----------- -----------------------
--- ------------------------------ -------------------------------------------
d) Aggregated information
* Aggregated volume N/A - single transaction
* Aggregated price
* Aggregated total
--- ------------------------------ -------------------------------------------
e) Date of the transaction 30 September 2016 (UK)
--- ------------------------------ -------------------------------------------
f) Place of the London Stock Exchange, AIM
transaction
--- ------------------------------ -------------------------------------------
-- ends -
Enquiries:
Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive
Officer
David Mackney, Chief Financial
Officer
Canaccord Genuity Limited (Nominated
Adviser and Joint Broker): +44 (0) 20 7523 8000
Dr Julian Feneley
Rupert Winckler
Henry Fitzgerald-O'Connor
Emma Gabriel
Shore Capital (Joint Broker): +44 (0)20 7408 4090
Bidhi Bhoma
Toby Gibbs
FTI Consulting: +44 (0) 20 3727 1000
Ben Atwell
Simon Conway
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage
pharmaceutical company with significant expertise in drug
development. The Group has three approved products: Tuzistra(R) XR,
targeting the US prescription cough-cold market; Moxatag(R) , a
once-a-day formulation of the antibiotic, amoxicillin, indicated
for the treatment of tonsillitis and/or pharyngitis secondary to
Streptococcus pyogenes in adults and pediatric patients 12 years
and older; and frovatriptan for the acute treatment of migraine. It
has an exclusive licensing agreement to develop and commercialise
multiple novel products focussed on the US prescription cough-cold
market as well as eight programmes in its NCE development pipeline.
Vernalis has also significant expertise in fragment and structure
based drug discovery which it leverages to enter into
collaborations with larger pharmaceutical companies. The Company's
technologies, capabilities and products have been endorsed over the
last five years by collaborations with leading pharmaceutical
companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK,
Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and
Tris.
For further information about Vernalis, please visit
www.vernalis.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHWGUGABUPQGCU
(END) Dow Jones Newswires
September 30, 2016 10:55 ET (14:55 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2024 to May 2024
Vernalis (LSE:VER)
Historical Stock Chart
From May 2023 to May 2024